Switch theme
Sign up to access all valuation multiples
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
2018
51
LTM Revenue n/a
LTM EBITDA n/a
-$19.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aerovate Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Aerovate Therapeutics achieved revenue of n/a and an EBITDA of -$81.3M.
Aerovate Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aerovate Therapeutics valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | XXX |
| Gross Profit | n/a | n/a | n/a | XXX | XXX |
| Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
| EBITDA | -$53.2M | -$81.3M | n/a | n/a | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | NaN% | NaN% | XXX |
| Net Profit | -$23.0M | -$51.5M | -$75.5M | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | NaN% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Aerovate Therapeutics's stock price is $2.
Aerovate Therapeutics has current market cap of $68.7M, and EV of -$19.5M.
See Aerovate Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$19.5M | $68.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Aerovate Therapeutics has market cap of $68.7M and EV of -$19.5M.
Aerovate Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Aerovate Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Aerovate Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$19.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAerovate Therapeutics's NTM/LTM revenue growth is n/a
Aerovate Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.6M for the same period.
Over next 12 months, Aerovate Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Aerovate Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Aerovate Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aerovate Therapeutics acquired XXX companies to date.
Last acquisition by Aerovate Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Aerovate Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Aerovate Therapeutics founded? | Aerovate Therapeutics was founded in 2018. |
| Where is Aerovate Therapeutics headquartered? | Aerovate Therapeutics is headquartered in United States of America. |
| How many employees does Aerovate Therapeutics have? | As of today, Aerovate Therapeutics has 51 employees. |
| Who is the CEO of Aerovate Therapeutics? | Aerovate Therapeutics's CEO is Mr. Timothy P. Noyes. |
| Is Aerovate Therapeutics publicy listed? | Yes, Aerovate Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Aerovate Therapeutics? | Aerovate Therapeutics trades under AVTE ticker. |
| When did Aerovate Therapeutics go public? | Aerovate Therapeutics went public in 2021. |
| Who are competitors of Aerovate Therapeutics? | Similar companies to Aerovate Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Aerovate Therapeutics? | Aerovate Therapeutics's current market cap is $68.7M |
| Is Aerovate Therapeutics profitable? | Yes, Aerovate Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
